Abstract:The liver is an important metabolic organ, and acute liver injury (ALI) is potentially lethal. Itaconate, a metabolic intermediate from the tricarboxylic acid cycle, showed emerging anti-oxidative and anti-inflammation properties, and an accumulating protective effect in multiple diseases, but its role in ALI still needs to be further explored. Here we established an ALI model induced by carbon tetrachloride in mice. Our results showed that 4-Octyl itaconate (OI), a derivate of itaconate, mitigated hepatic damage by improving liver function, reducing histopathological damage, and decreasing the death of hepatocytes. Additionally, OI decreased myeloperoxidase and thiobarbituric acid reactive substances (TBARS) levels in the ALI model. OI also inhibited the inflammatory response by reducing pro-inflammatory cytokine secretion (IL-6, TNF-α, IL-1β, and MCP-1) and infiltration of macrophages and neutrophils in the ALI model. However, administration of ML385, a specified Nrf2 inhibitor, eliminated the protective properties of OI in the CCl4-induced liver injury model by increasing hepatic damage and oxidative stress. Furthermore, OI increased the expression and nuclear translocation of Nrf2 and elevated the expression of heme oxygenase-1 and NAD(P)H quinone oxidoreductase 1, while knockdown of Nrf2 eliminated these effects in murine hepatocyte NCTC 1469 under CCl4 treatment. Moreover, we found that OI reduced serum High-mobility group box 1 (HMGB1) levels in CCl4-treated mice. Finally, OI inhibited nuclear translocation of factor-kappa B (NF-κB) and inflammatory cytokine production in murine macrophages. In conclusion, these results indicated that OI ameliorated CCl4-induced ALI by mitigating oxidative stress and the inflammatory response. The possible mechanism was associated with the elevation of Nrf2 nuclear translocation and inhibition of HMGB1 mediated the nuclear translocation of NF-κB.

4-Octyl itaconate restricts STING activation by blocking its palmitoylation

4-Octyl Itaconate As a Metabolite Derivative Inhibits Inflammation Via Alkylation of STING

Itaconate is a Lysosomal Inducer That Promotes Antibacterial Innate Immunity.

Itaconate Regulates Macrophage Function Through Stressful Iron-Sulfur Cluster Disrupting And Iron Metabolism Rebalancing

STING Directly Recruits WIPI2 for Autophagosome Formation During STING-induced Autophagy.

Human STING oligomer function is governed by palmitoylation of an evolutionarily conserved cysteine

4-Octyl Itaconate Inhibits Poly(i:C)-Induced Interferon-Β Secretion in Mouse Bone Marrow-Derived Macrophages Partially by Activating Nrf2

4-Octyl itaconate inhibits aerobic glycolysis by targeting GAPDH to exert anti-inflammatory effects

4-octyl itaconate ameliorates alveolar macrophage pyroptosis against ARDS via rescuing mitochondrial dysfunction and suppressing the cGAS/STING pathway

Targeting STING oligomerization with licochalcone D ameliorates STING-driven inflammatory diseases

Targeting STING oligomerization with small-molecule inhibitors

4-OI Attenuates Carbon Tetrachloride-Induced Hepatic Injury via Regulating Oxidative Stress and the Inflammatory Response

Structural Insights into a Shared Mechanism of Human STING Activation by a Potent Agonist and an Autoimmune Disease-Associated Mutation.

CDK inhibitor Palbociclib targets STING to alleviate autoinflammation

Itaconate inhibits TET DNA dioxygenases to dampen inflammatory responses

A Novel Transcript Isoform of STING That Sequesters Cgamp and Dominantly Inhibits Innate Nucleic Acid Sensing

Octyl Itaconate Inhibits Osteoclastogenesis by Suppressing Hrd1 and Activating Nrf2 Signaling

Itaconate and Itaconate Derivatives Target JAK1 to Suppress Alternative Activation of Macrophages.

STING inhibitors target the cyclic dinucleotide binding pocket

A clinically-relevant STING agonist restrains human TH17 cell inflammatory profile

4-Octyl Itaconate Prevents Free Fatty Acid-Induced Lipid Metabolism Disorder through Activating Nrf2-AMPK Signaling Pathway in Hepatocytes